Letybo (Botulinum Toxin Type A)

Letybo (Botulinum Toxin Type A) acts on the neuromuscular junction to alleviate muscle overactivity in several therapeutic areas.

• Cervical dystonia: reduces abnormal neck muscle contractions, improving head posture and pain.
• Chronic migraine: decreases frequency of migraine attacks by targeting pericranial muscles.
• Blepharospasm: relaxes overactive eyelid muscles, reducing involuntary blinking.
• Upper limb spasticity: diminishes muscle tone in the arm, enhancing functional movement.
• Severe axillary hyperhidrosis: blocks sympathetic nerve signals to sweat glands, reducing excessive sweating.

• Botulinum toxin type A is a protein that cleaves SNAP‑25, a component of the SNARE complex required for vesicle fusion. By disrupting SNAP‑25, the toxin prevents the release of acetylcholine from presynaptic nerve terminals at the neuromuscular junction, resulting in temporary inhibition of muscle contraction. The effect is localized to the injection site and typically lasts for several months as new nerve terminals regenerate.

Adverse reactions to Letybo are generally related to the injection site and the pharmacologic action of the toxin.

Common Side Effects

• Injection site pain
• Bruising or hematoma
• Headache
• Neck weakness
• Dry mouth
• Flu‑like symptoms

Serious or Rare Side Effects

• Dysphagia or difficulty swallowing
• Respiratory compromise
• Systemic botulism‑like syndrome
• Vision changes such as blurred vision
• Generalized muscle weakness
• Severe allergic reaction (anaphylaxis)

Before administering Letybo, clinicians should evaluate patient history and follow specific safety measures.

• Assess for infection: avoid injection in areas with active skin infection.
• Contraindications: do not use in patients with known hypersensitivity to botulinum toxin or its excipients.
• Pregnancy and lactation: safety not established; use only if potential benefit justifies risk.
• Pediatric use: limit to approved indications and adjust dosing carefully.
• Monitor for toxin spread: observe for signs of distant muscle weakness or dysphagia.
• Avoid concurrent use of aminoglycoside antibiotics or other neuromuscular blocking agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Letybo may interact with other medications that influence neuromuscular transmission or affect clotting.

Major Interactions (Avoid)

• Aminoglycoside antibiotics (e.g., gentamicin): may potentiate neuromuscular blockade.
• Muscle relaxants (e.g., dantrolene): increase risk of severe weakness.
• Other botulinum toxin products: cumulative toxicity risk.
• Cholinesterase inhibitors (e.g., pyridostigmine): may reduce therapeutic effect.
• General anesthetics that affect neuromuscular function.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): may increase bruising at injection sites.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): similar bruising risk.
• Antihistamines: may mask early signs of allergic reaction.
• Beta‑blockers: potential influence on cardiovascular response.
• Corticosteroids: may affect local tissue healing.